Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A report just published on line in Nature Medicine describes the first use of intraoperative, tumor-specific fluorescence imaging to highlight the precise position of small groups of cancer cells in women with ovarian cancer, thereby allowing the surgeon to carefully excise such small groups of cells.
Filed under: Management, Treatment | Tagged: cells, excision, fluorescence, imaging, surgery, tumor | Leave a Comment »
An article in the June issue of the journal Acta Oncologia discusses the potential of newer types of imaging technology as methods to monitor the progression of disease in men with castrate-resistant prostate cancer (CRPC).
Filed under: Living with Prostate Cancer, Management | Tagged: castrate-resistant, imaging | Leave a Comment »
With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Endocyte, imaging, prostate cancer-specific, Purdue | Leave a Comment »
According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: 123I-MIP-1072, agent, imaging, PMSA, Trofex | 2 Comments »
There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice: Angiogenic effect of a specific statin on prostate cancer development Synergistic impact of calcitriol on cryotherapy Hybrid imaging techniques and prostate cancer GTI-2040 in treatment of CRPC
Filed under: Drugs in development, Management, Risk, Treatment | Tagged: angiogenesis, calcitriol, cryotherapy, GTI-2040, hybrid, imaging, statin, synergy | Leave a Comment »
It is probably fair to say that readers should expect little in the way of revolutionary new information affecting the management of prostate cancer from this year’s annual meeting of the American Urological Association (AUA). However,
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: active surveillance, imaging, Management, screening | 4 Comments »
In today’s new reports we summarize information from recent papers dealing with: Apical biopsy cores in initial diagnosis of prostate cancer Imaging studies in the initial work-up of newly diagnosed patients Intrafascial dissection of peri-prostatic tissue during laparoscopic surgery Similarity of short-term rates of biochemical recurrence after open surgery or RALP Does how we define [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: apex, biochemical recurrence, biopsy, Diagnosis, dissection, imaging, intrafascial, open, RALP, risk, robot-assisted, surgery, work-up | 1 Comment »
Today’s news reports cover such matters as: Genistein as a prostate cancer stimulating agent Molecular characterization of advanced prostate cancers Imaging technology and focal therapy
Filed under: Diagnosis, Management, Prevention, Risk, Treatment | Tagged: focal therapy, gene expression signature, genistein, imaging | Leave a Comment »
On March 23, the following letter was sent by several members of the US House of Representatives to the acting director of the National Institutes of Health and the director of the National Cancer Institute:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: imaging, research | 5 Comments »
According to a recent press release a group of more than 40 leaders from academia, industry, philanthropy, and advocacy called today for the Obama Administration, Congress, the National Institutes of Health, and the Department of Defense to increase federal funding for research into imaging technologies for less invasive and more accurate diagnosis of prostate cancer.
Filed under: Diagnosis, Management | Tagged: Diagnosis, imaging, research | 5 Comments »
We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today:
Filed under: Diagnosis, Management | Tagged: Diagnosis, endoglin, imaging, PCA3, staging | Leave a Comment »
Today’s prostate cancer news update includes information related to the following areas: Long-term survival of patients with PSA levels ≥ 50 ng/mL who have been treated with radical prostatectomy The current role of bone imaging in the managment of prostate cancer The potential of targeted therapy for androgen-independent prostate cancer, based on expression of specific molecular markers
Filed under: Drugs in development, Management, Treatment | Tagged: androgen-independent, bone, cancer, imaging, news, prostate, prostatectomy, radical, survival, targeted, therapy, update | Leave a Comment »
Articles summarized in this weekend news update include information about: The value of endorectal MRI imaging in staging patients with respect to whether they have cancer confined to the prostate or extracapsular disease Patterns of disease recurrence after salvage radical prostatectomy for patients with radiation-recurrent disease The potential of PSA kinetics to improve prediction of likelihood for [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cancer, endorectal, imaging, prostate, PSA, PSA velocity, replacement, salvage, staging, survival, testosterone | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site